947 related articles for article (PubMed ID: 29456043)
1. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
2. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
[TBL] [Abstract][Full Text] [Related]
3. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A; Lellouche J; Temkin E; Daikos G; Skiada A; Durante-Mangoni E; Dishon-Benattar Y; Bitterman R; Yahav D; Daitch V; Bernardo M; Iossa D; Zusman O; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L; Paul M; Carmeli Y;
Clin Microbiol Infect; 2020 Sep; 26(9):1185-1191. PubMed ID: 32251844
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
6. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Daitch V; Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Cavezza G; Adler A; Dickstein Y; Pavleas I; Zampino R; Bitterman R; Zayyad H; Koppel F; Zak-Doron Y; Levi I; Babich T; Turjeman A; Ben-Zvi H; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
BMC Infect Dis; 2021 Mar; 21(1):309. PubMed ID: 33789574
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
8. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.
Cisneros JM; Rosso-Fernández CM; Roca-Oporto C; De Pascale G; Jiménez-Jorge S; Fernández-Hinojosa E; Matthaiou DK; Ramírez P; Díaz-Miguel RO; Estella A; Antonelli M; Dimopoulos G; Garnacho-Montero J;
Crit Care; 2019 Nov; 23(1):383. PubMed ID: 31779711
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
[TBL] [Abstract][Full Text] [Related]
10. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
[TBL] [Abstract][Full Text] [Related]
11. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
Li KL; Abad CLR
Int J Infect Dis; 2020 Apr; 93():9-14. PubMed ID: 31978579
[TBL] [Abstract][Full Text] [Related]
12. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.
Parchem NL; Bauer KA; Cook CH; Mangino JE; Jones CD; Porter K; Murphy CV
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1433-9. PubMed ID: 27230510
[TBL] [Abstract][Full Text] [Related]
13. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
[TBL] [Abstract][Full Text] [Related]
15. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for carbapenem-resistant Gram-negative bacteria.
Paul M; Carmeli Y; Durante-Mangoni E; Mouton JW; Tacconelli E; Theuretzbacher U; Mussini C; Leibovici L
J Antimicrob Chemother; 2014 Sep; 69(9):2305-9. PubMed ID: 24872346
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial.
Rosso-Fernández C; Garnacho-Montero J; Antonelli M; Dimopoulos G; Cisneros JM;
Trials; 2015 Mar; 16():102. PubMed ID: 25872790
[TBL] [Abstract][Full Text] [Related]
18. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
20. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
Gibson GA; Bauer SR; Neuner EA; Bass SN; Lam SW
Antimicrob Agents Chemother; 2016 Jan; 60(1):431-6. PubMed ID: 26525802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
